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Activation of the inflammatory system occurs in most patients with advanced 
heart failure, regardless of etiology, and contributes to the pathophysiological 
milieu and the progression of the disease. The term inflammatory cardiomyopathy 
(ICM) refers to a group of disorders for which an acute or chronic myocardial 
inflammation is the central cause of abnormal cardiac structure or impaired cardiac 
function. The most common cause of inflammatory cardiomyopathy is lymphocytic 
myocarditis, which is most usually triggered by a viral infection, and occasionally 
by other infectious agents. Rare causes of specific inflammatory cardiomyopa-
thies include cardiac sarcoidosis, giant cell myocarditis and eosinophilic myocarditis. 
Inflammatory cardiomyopathy can also occur in connection with autoimmune 
inflammatory diseases. Typical manifestations of inflammatory cardiomyopathy 
include chest pain, heart failure, and arrhythmias, but these symptoms and signs 
are unspecific. Although non-invasive diagnostic methods are emerging, the gold 
standard of diagnosis is the histological examination of an endomyocardial biopsy. 
Owing to the invasive nature of this technique and a modest diagnostic sensitivity, 
its use is limited. Therefore, the identification of inflammatory cardiomyopathy 
is elusive and the true incidence of the condition remains unknown. In most cases 
of lymphocytic myocarditis, recovery occurs within a few weeks following sup-
portive treatment. In patients with cardiac sarcoidosis, giant cell myocarditis or 
eosinophilic myocarditis the use of immunosuppressive treatment is recommended, 
as is the case in myocarditis associated with autoimmune disorders. Such interven-
tions may also have beneficial effects in chronic viral myocarditis once the virus has 
been cleared. In severe cases, treatment with mechanical circulatory support and/
or heart transplantation may be required. Randomized intervention trials including 
antiviral, immunomodulating, or immunosuppressive agents are lacking. Similarly, 
new molecular-based methods and therapies tailored to specific pathogeneses 
have a potential to improve diagnosis and outcomes in patients with inflammatory 
cardiomyopathy. Still, such techniques and interventions are to be evaluated in 
adequate randomized controlled studies.
Keywords: myocarditis, inflammatory cardiomyopathy, lymphocytic myocarditis, 
cardiac sarcoidosis, giant cell myocarditis, eosinophilic myocarditis, heart failure, 
endomyocardial biopsy
1. Introduction
Myocarditis implies the presence of diffuse or focal inflammation in the  
cardiac muscle [1]. Although inflammation of the myocardium can be induced by 
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a wide variety of autoimmune disorders, hypersensitivity reactions and toxins, 
the predominant etiopathogenetic factor is infectious agents; these are mostly 
viral, but can also include bacterial and protozoal microbes [1, 2]. Still, in the 
individual case the etiology can be difficult to identify. Inflammatory cardio-
myopathy refers to a broad group of disorders for which inflammation of the 
myocardium represents the principal cause of ventricular remodeling and cardiac 
dysfunction (Figure 1) [3, 4]. This term is rather unspecific since as several 
cardiomyopathies a low degree of inflammation is present and an infectious 
agent can seldom be identified [1]. In contrast to hereditary cardiomyopathies, 
no monogenetic diseases cause inflammatory cardiomyopathy, although a genetic 
predisposition towards cardiotropic viruses and/or autoimmune reactions may 
occur in certain individuals [2, 5].
Myocarditis and inflammatory cardiomyopathy can be acute, subacute, or 
chronic [1]. The incidence and prevalence of these conditions are difficult to 
estimate as many cases are asymptomatic [2, 6] and the diagnosis is seldom  
verified with an endomyocardial biopsy (EMB) [7]. Nevertheless, myocarditis 
and inflammatory cardiomyopathy are noteworthy conditions related to poor 
outcomes, especially when complicated by heart failure and ventricular  
arrhythmias [5, 8]. This chapter will focus on cardiomyopathies associated with 
impaired cardiac structure and function for which inflammation is the pri-
mary cause.
2. Myocarditis and inflammatory cardiomyopathy
The previous histopathological diagnosis of myocarditis has traditionally been 
defined according to the Dallas criteria of 1986, which requires the presence of 
inflammatory cell infiltrates in the myocardial tissue and advocate classification 
into active forms with myocytolysis and borderline forms without cell necrosis 
[1, 5]. A histological diagnosis requires an endomyocardial biopsy, which is not only 
Figure 1. 
Inflammatory cardiomyopathy (ICM) refers to a broad group of disorders for which inflammation of the 
myocardium represents the principal cause of ventricular remodeling and cardiac dysfunction.
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resource-intensive, but also invasive with attendant potential for complications [9]. 
The Dallas criteria represented the first attempt to develop standardized diagnostic 
guidelines for the histopathological classification of myocarditis [10]. However, the 
practical use of these criteria is limited by their low sensitivity owing to variation  
in collection of the samples and inter-observer variability between different 
pathologists [7, 11].
In addition to histological examination, an endomyocardial biopsy can be exam-
ined with polymerase chain reaction (PCR) techniques to screen for cardiotropic 
viruses and with immunohistochemical methods to detect low-grade inflammation 
[1]. The value of these analyses is still unclear, however, as the results do not provide 
a clear guide with respect to the management and prognosis of inflammatory 
cardiomyopathy. For these reasons, many practitioners refrain from obtaining 
endomyocardial biopsies, with the result that myocarditis often becomes an exclu-
sion diagnosis based on clinical features and other clinical examinations [1].
Cardiac magnetic resonance (MR) has been used more extensively in recent 
years to diagnose and exclude myocarditis and inflammatory cardiomyopathy 
(Figure 2A) [12]. The ‘Lake Louise criteria’, a consensus guide to cardiac MR in 
myocardial inflammation were published in 2009 [13]. These criteria focused on 
three diagnostic targets in the myocardial tissue derived from a signal intensity 
assessment in T2-weighted images with early and late gadolinium enhancement: 1) 
edema; 2) hyperemia; and 3) necrosis or scar. A high likelihood of myocarditis is 
assumed to occur if two out of these three criteria are positive [13]. The Lake Louise 
Criteria have subsequently been widely used in both clinical and research settings.
18Ffluoro-deoxy-glucose (FDG) positron emission tomography/computed 
tomography (PET/CT) is emerging as a diagnostic tool for the assessment of 
myocarditis and inflammatory cardiomyopathy (Figure 2B) [14]. As the activation 
of inflammatory cells is associated with increased glucose utilization, [15] myo-
carditis can be detected by PET after intravenous administration of FDG. The CT 
is added to identify the localization of myocardial inflammation, which correlates 
anatomically with increased glucose turnover. As compared with cardiac MR, 
Figure 2. 
Images from a patient with cardiac sarcoidosis: A) cardiac MR (T2-weighted image) showing delayed 
enhancement (arrow) indicating inflammation and B) PET/CT displaying a general increase in glucose uptake 
in the cardiac muscle also indicating inflammation. Figure courtesy of Dr. Christian Polte.
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PET/CT is associated with reduced radiation exposure, and demonstrates higher 
sensitivity of for mild or borderline myocarditis, and increased specificity for 
chronic myocarditis [14].
3. Etiology
Cardiotropic viruses are the commonest causes of myocarditis in Europe and North 
America [2]. The most frequently-encountered etiological agents include enterovirus 
(Coxsackie B virus), adenovirus and parvovirus. Other viruses that are sometimes 
detected include influenza virus, hepatitis C virus, and HIV. The spirochete bacterium, 
Borrelia burgdorferi, may in rare cases cause myocarditis, which mainly affects the 
cardiac electrical system resulting in atrioventricular (AV) block [2, 5].
Chagas’ disease (American trypanosomiasis) is prevalent various countries 
of Central-and South America. The infection is caused by Trypanosoma cruzi, 
which is a protozoan parasite transmitted to humans by various species of 
triatomine bugs [16]. Trypanosoma cruzi can cause both acute myocarditis and 
a chronic inflammation leading to severe cardiomyopathy and advanced heart 
failure [16].
Myocarditis can also occur in connection with autoimmune diseases, mainly 
systemic lupus erythematosus, systemic sclerosis, and rheumatoid arthritis. 
Various pharmaceuticals and chemicals can cause myocarditis via a toxic or 
allergic reaction affecting the heart. Radiation, heat stroke and hypothermia  
are examples of physical injuries that have been associated with cardiac  
inflammation [1, 2].
4. Pathophysiology
The pathophysiological mechanisms of lymphocytic myocarditis have been 
studied in animal models for Coxsackie B virus and other cardiotropic viruses [17]. 
Coxsackie B virus, which is an RNA virus, is incorporated into the myocyte via a 
receptor and mediated endocytosis, after which virus replication occurs in the cyto-
plasm [2, 18]. Following toxic cell necrosis, the virus particles come into contact 
with the myocardial interstitial tissue and trigger an innate immune response. The 
myocardial tissue becomes infiltrated by macrophages and natural killer (NK) cells, 
which eliminate infected myocytes and produce several cytokines, including virus-
inhibiting interferon and tumor necrosis factor-α (TNF-α), a cardio-depressant [2]. 
Over time, the adaptive immune system is also stimulated, leading to recruitment of 
cytotoxic T-cells and neutralizing antibodies that contribute to viral clearance. An 
experimental form of viral myocarditis has been proposed to cause cardiomyopathy 
through three different mechanisms (Figure 3) [2].
1. Adequate immune activation leads to healing of the myocarditis within two to 
three weeks, but the damage is so extensive that a clinical phenotype of dilated 
cardiomyopathy arises [18].
2. An upregulated and overactive immune response may cause tissue  
damage through infiltrations of T-cells and autoantibodies (autoimmune  
cardiomyopathy).
3. A downregulated and ineffective immune response can lead to continuous 
apoptosis through a persistence virus infection (viral cardiomyopathy) [1].
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Findings that support the relationship between cardiotropic viruses and the 
development of cardiomyopathy in human studies include disturbances of T-cell 
regulation, inadequate expression of human leucocyte antigens (HLA) expressed 
and the presence of autoantibodies against cardiac epitopes [2].
5. Clinical features
Patients with myocarditis or inflammatory cardiomyopathy may present with 
a wide variety of symptoms and signs. The spectrum ranges from asymptomatic 
patients with minor changes on the electrocardiogram (ECG), or echocardiogram, 
to patients with fatigue, breathlessness, and palpitations and syncope due to 
impaired cardiac function or arrhythmias, and finally to patients with circulatory 
shock as a consequence of fulminant heart failure [19]. In some cases, the clinical 
presentation is preceded by influenza symptoms, upper respiratory tract infection 
or gastrointestinal discomfort, but in many cases, there are no prodromal  
symptoms [8].
Despite a large heterogeneity of the clinical picture, a few distinct forms can be 
identified.
1. Acute lymphocytic myocarditis presents with chest symptoms, comprising 
discomfort, pain, or palpitations, often combined with fatigue or breathlessness 
[19]. Fever and signs of infection can accompany the symptoms and myocardial 
biomarkers are frequently elevated. The ECG shows ST-T changes or arrhyth-
mias and an echocardiogram can show regional hypokinesia or impaired systolic 
function [20]. The most usual differential diagnosis is acute coronary syndrome, 
which in most cases requires an exclusionary coronary angiogram. The treatment 
is mainly supportive (Figure 4A).
2. Fulminant myocarditis is an unusual but a very serious condition [6, 21]. 
The patient presents with cardiogenic chock including hypotension, tachy-
cardia, and anuria without any other explanation for heart failure [22]. 
Figure 3. 
An experimental form of viral myocarditis has been proposed to cause cardiomyopathy through three different 
mechanisms.
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The echocardiogram displays poor ventricular contractility without dilation 
and a myocardial biopsy can be normal or show a varying degree of inflam-
mation [22]. Such patients often require intensive care, with administration 
of an inotropic and/or vasoconstrictive drug and, in some case short-term 
mechanical circulatory support (MCS) [4]. The pronounced ventricular 
failure frequently recovers within a few weeks. It has been speculated that 
the temporary cardio-depressive feature can be caused by an extensive storm 
of toxic cytokines, which would explain why the myocardial biopsy can be 
normal [21].
3. Cardiac sarcoidosis, giant cell myocarditis and eosinophilic myocarditis 
are examples of three additional clinical entities, which will be discussed 
 separately below.
6. Diagnostics
Laboratory analysis often reveals elevation of inflammatory activity and 
increases in circulating markers of myocardial injury, such as creatine kinase (CK) 
and troponin [8]. Elevation of natriuretic peptides indicates overt heart failure. 
Figure 4. 
Histopathological findings on endomyocardial biopsies from patients with inflammatory cardiomyopathy 
(tissue-staining with hematoxylin and eosin). A) Lymphocytic myocarditis. Dense lymphocytic cell 
infiltration with some residual cardiomyocytes. B) Cardiac sarcoidosis. Non-caseating epithelioid cell 
granulomas (arrows) and fibrosis. C) Giant cell myocarditis. Widespread myocardial lesions with 
degenerated and necrotic cardiomyocytes and infiltration of mononuclear inflammatory cells, giant 
multinuclear cells (arrow) and some eosinophils. D) Eosinophilic myocarditis. Massive interstitial 
eosinophilic cell infiltration. Figure courtesy of prof. Anders Oldfors.
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Virus serology is seldom conclusive. An ECG can show unspecific ST-T changes, 
T-wave inversions, AV block or tachyarrhythmia [20]. An echocardiogram can 
detect regional hypokinesia, as well as ventricular dilation and reduced ejection 
fraction [23]. A suspicion of myocarditis most often arises after a coronary angio-
gram has excluded an underlying coronary artery disease.
Cardiac MR is used for the workup of suspected myocarditis. With delayed 
enhancement techniques, general or focal accumulation of contrast can be 
seen, which differs from ischemic injuries and can be of value when deciding 
the localization of an endomyocardial biopsy [24]. The Lake Louise criteria can 
be applied to evaluate the likelihood for myocardial inflammation. A PET/CT 
that shows increased focal or general myocardial uptake of FDG supports the 
diagnosis.
An endomyocardial biopsy should be considered when acute or chronic heart 
failure of unclear genesis presents, as well as in patients with impaired left ventricu-
lar function of unknown etiology with contemporary arrhythmias of ventricular 
origin or a significant AV block [9]. If myocarditis is diagnosed this will influence 
treatment and determine the prognosis. Even if a myocardial biopsy is limited by 
suboptimal sensitivity and some risk, this investigation still serves as a pivotal tool 
for diagnosis of myocardial inflammation [7].
7. Treatment
Treatment of myocarditis and inflammatory cardiomyopathy is mainly support-
ive and conforms with standard medical therapy for other dilated cardiomyopathies 
[6]. Patients should receive conventional, guideline-directed medical heart failure 
treatment including beta-blockers, inhibition of the renin-angiotensin-aldosterone 
system with angiotensin-converting enzyme (ACE) inhibitors or an angiotensin-
receptor blocker (ARB), or as applied more recently, valsartan/sacubitril (an ARB 
combined with a neprilysin inhibitor [ARNI]), as well as a mineral corticoid antago-
nist (spironolactone or eplerenone) [25]. Sodium–glucose cotransporter-2 (SGLT-2) 
inhibitors are emerging as a new oral new therapy for heart failure patients who have 
reduced ejection fraction and are added to conventional therapy for patients both 
with or without diabetes [26, 27]. Loop diuretics should be added in patients who 
show signs of fluid retention [28]. If necessary, anti-arrhythmic therapy involving a 
pacemaker (PM) and/or an implantable cardioverter defibrillator (ICD) is indicated 
[6]. With severe heart failure, inotropic support may be necessary, or alternatively a 
short-term MCS [22]. The role of immunosuppression in myocarditis is controversial 
and its use as a general strategy is not advocated [29, 30].
Persons with acute myocarditis and mild myocardial infection frequently recover 
without any sequelae, but should refrain from heavy physical activity or sporting for 
at least 3 months due to an increased risk of ventricular arrhythmias [4].
8. Cardiac sarcoidosis
Sarcoidosis is a multisystem inflammatory disease of unknown etiology charac-
terized by the presence of mononuclear phagocytes and non-caseating granuloma 
in different organ systems [31]. Although clinical heart disease has been confirmed 
in around 5% of patients with systemic sarcoidosis, up to 25% of such patients 
display signs of cardiac sarcoidosis at autopsy, indicating asymptomatic cardiac 
disease [32, 33].
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The incidence of cardiac involvement varies between different ethnic groups: for 
example cardiac sarcoidosis is much more common among Japanese patients and 
African Americans than Caucasians [31]. A pronounced myocardial fibrosis can 
lead to a mixed picture of restrictive and dilated cardiomyopathy. The conduction 
system is more often affected in cardiac sarcoidosis than in other inflammatory 
cardiomyopathies, possibly due to an inflammation that is located in the atrium 
and the antero-septal wall of the left ventricle, which frequently leads to AV block 
[34, 35]. Granuloma formation can occur in all parts of the heart, but the cardiac 
valves and coronary arteries are usually spared [31]. The pericardium may also be 
involved, and pericardial fluid is present in 5-15% of cases [31].
It has been suggested that the incidence of cardiac sarcoidosis is increasing [36]. 
In the US, the incidence of transplant patients with cardiac sarcoidosis as their 
underlying condition increased from 0.1% to 0.5% between 1994 and 2014 [37]. 
Similar trends were reported from a Finnish nationwide cohort study [36]. However, 
this increase in incidence may be due to a progress in imaging techniques, increasing 
awareness and more aggressive diagnostics involving endomyocardial biopsies [36].
8.1 Etiology
Sarcoidosis is an inflammatory disease whose pathogenesis and inciting events 
are not well understood. Accumulating evidence suggests that the disease is caused 
by an immunological response to an antigenic trigger of unknown origin in geneti-
cally susceptible individuals [38]. Supportive of this are alleles of the HLA-DRB1 
locus, which are more common in patients with sarcoidosis [39]. In addition, expo-
sure to environmental triggers and to various micro-organisms have been linked to 
the development of the disease [40].
8.2 Pathophysiology
Non-caseating granulomas are the histopathological hallmark of cardiac sar-
coidosis (Figure 4B). The granuloma consists of a tightly packed follicle made 
up of lymphocytes (in particular CD4+ T cells), giant cells and epithelioid cells 
surrounded by a rim of fibroblasts and lymphocytes [41].
Clinical features of cardiac sarcoidosis depend on the location, extent, and activ-
ity of the disease. Cardiac sarcoidosis can also occur without clinical manifestations 
[31], but common symptoms include palpitations, dizziness and/or fainting [36]. 
Symptomatic cardiac sarcoidosis is a potentially serious condition that can lead to 
heart failure, life-threatening arrhythmias, and sudden death [42, 43].
8.3 Diagnostics
Emergence of symptoms and signs of heart disease in patients with known 
extracardiac sarcoidosis, especially young individuals with electrical conduction 
disturbances, should raise the suspicion of cardiac sarcoidosis. A careful history 
should be obtained with respect to palpitations, syncope and pre-syncope [31, 44]. 
An ECG may reveal unspecific ST-T changes, T-inversions, conduction disturbances 
or ventricular arrhythmias. Long-term electrocardiography can provide valuable 
additional information in the form of the numbers of both supraventricular and 
ventricular premature extra-systoles and supraventricular and ventricular tackyar-
rhythmias [45]. In clinically silent cardiac sarcoidosis, the echocardiogram is often 
normal, but with manifest disease, structural and functional aberrations become 
apparent [45, 46]. Those defects are variable and usually non-specific, although inter-
ventricular thinning, especially basal, left and/or right ventricle diastolic and systolic 
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dysfunction, and isolated wall motion abnormalities, may indicate cardiac sarcoidosis 
[31]. Cardiac MR, and to an increasing extent FDG-PET/CT, are today considered to 
be the best methods for detecting and visualizing sarcoidosis in the heart muscle [31]. 
Both techniques can visualize active inflammation (Figure 2) [47–49]. Although the 
pattern of late gadolinium enhancement on Cardiac MR is usually patchy and multifo-
cal, with sparing of the endocardial border, this is neither specific nor diagnostic for 
cardiac sarcoidosis [50, 51]. An endomyocardial biopsy that displays non-caseating 
granulomas strongly supports the diagnosis, but is not pathognomonic.
In patients with extra-cardiac sarcoidosis, a lymph node or lung biopsy is typi-
cally preferred to endomyocardial biopsy because of the lesser procedural risk and 
higher diagnostic yield [36, 48]. However, in the case of a negative extra-cardiac 
biopsy, an endomyocardial biopsy may be required. Nevertheless, owing to the 
patchy distribution of the disease, and endomyocardial biopsy reveals non-caseat-
ing granulomas in less than 25% of patients [52].
8.4 Treatment
A strong suspicion of cardiac sarcoidosis motivates treatment with high dose 
corticosteroids with slow tapering. Studies have shown regression of high-grade AV 
block after corticosteroid treatment, as well as a reduced frequency of ventricular 
arrhythmias in the acute phase of the disease [53]. Most patients - but not all - 
benefit from this treatment. Methotrexate is also an option, but is mainly given to 
facilitate tapering of steroids and, thus, alleviate their side effects [31]. The optimal 
treatment period for corticosteroids is still debated, but should not be less than one 
year and, in most cases, should be longer. If a decision is made to end corticosteroid 
treatment, it is important to follow the patient closely for possible relapse, espe-
cially during the first year [36].
Antiarrhythmic drugs usually have only a limited effect on rhythm disturbances 
in patients with cardiac sarcoidosis. Beta-blockers are the first choice for both 
supraventricular and ventricular arrhythmias [53] and amiodarone can be tested 
in acute situations with ventricular tachycardia (VT). If the arrhythmia events are 
associated with active inflammation, corticosteroids should be added or their dose 
increased. If satisfactory results are not achieved, VT ablation may be considered 
[34, 35]. Class I anti-arrhythmic agents are not recommended in patients with 
cardiac sarcoidosis as most patients have structural myocardial changes in the form 
of myocardial fibrosis. Because of the tendency towards persistent VT attacks and 
a high risk of sudden death, implantation of an ICD must be considered and should 
be discussed with the patient at an early stage. A recent international consensus 
document on sarcoidosis-related arrhythmias provides guidance on which patients 
should be considered for ICD implantation [34]. In those with a high-grade AV 
block, an implantation of a permanent pacemaker is indicated [44].
Heart failure owing to cardiac sarcoidosis should always be treated with 
guideline-directed medical therapy, as described above. Heart transplantation is 
an option for patients in NYHA functional class IIIB-IV or in those with intractable 
arrhythmias, with satisfactory outcomes [54]. However, there is a risk of recurrence 
of the sarcoidosis in the transplanted heart and little is known about long-term 
morbidity and mortality in this group after heart transplantation [55].
9. Giant cell myocarditis
Giant cell myocarditis (GCM) is a rare inflammatory heart disease of unknown 
etiology, which is associated with thymoma, inflammatory bowel disease and 
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other autoimmune disorders [1]. The myocardial inflammation is characterized by 
widespread infiltration of giant cells along with several other inflammatory cell 
types that cause myocyte destruction [43]. Giant cells themselves are abnormal cell 
masses generated by the fusion of several macrophages (Figure 4C). Evidence sug-
gests that this phenomenon may arise in response to immune dysregulation medi-
ated by T-lymphocytes [43]. Giant cell myocarditis has been commonly depicted as 
a rapidly progressive and usually fatal condition for which heart transplantation is 
the treatment of choice [56]. The disease caught attention in the 1990’s when the 
International Multicenter Giant Cell Myocarditis Study Group reported that 89% 
of the 63 included patients with the disease either required heart transplantation or 
died. The median transplant-free survival rate was only 5.5 months [56]. In a later 
analysis, the overall transplant-free survival at 5 years in patients with giant cell 
myocarditis was reported to be as low as 10% [57]. However, previous epidemio-
logical studies are confounded by the fact that most patients were diagnosed after 
heart transplantation or at autopsy.
The initial symptoms of giant cell myocarditis comprise chest pain, palpita-
tions, fatigue, breathlessness and ankle swelling. Individuals with giant cell myo-
carditis often exhibit advanced heart failure and life-threating arrhythmias [21]. 
Endomyocardial biopsy is the gold standard for diagnosis [9]. Cardiac MR and PET/
CT are useful for identifying targets for biopsy. The combination of cardiac MR  
and endomyocardial biopsy has been shown to improve detection rates. When a 
clinical suspicion remains high despite a negative biopsy, repeat sampling is  
recommended [1].
Patients who are diagnosed in the early phase of the disease may respond to 
immunosuppressive treatment, including calcineurin inhibitors (tacrolimus or 
cyclosporine), an antimetabolite (mycophenolate mofetil or azathioprine) and 
prednisolone, but an ongoing disease process rapidly damages the heart, which is 
why heart transplantation often becomes the only realistic treatment option. Owing 
to the severity of heart failure and the presence of treatment-resistant ventricular 
arrhythmias, patients with giant cell myocarditis frequently develop multiorgan 
failure and require durable mechanical support with either a left ventricular or a 
bi-ventricular assist device as a bridge-to-transplantation [55]. Patients treated 
with combined immunosuppression have a median survival of 12.3 months from 
the onset of symptoms, compared to 3.0 months without immunosuppression [58]. 
Early and aggressive arrhythmia management, including radiofrequency catheter 
ablation, has been suggested to prolong survival [59]. Early initiation of immuno-
suppressive therapy also seems to improve outcomes in patients with this aggressive 
cardiac disease [59].
10. Eosinophilic myocarditis
Eosinophilic myocarditis is a rare and potentially lethal disease characterized by 
eosinophilic infiltrates in the myocardial tissue (Figure 4D). It may occur in asso-
ciation with malignancy, parasite infection, hypersensitivity, and also an idiopathic 
hyper-eosinophilic syndrome [60, 61]. However, the relative associations between 
proposed triggers and myocardial eosinophilia remain elusive and, in most cases, 
the underlying cause remains unknown [1, 60]. The clinical presentation can range 
from mild symptoms to chronic restrictive cardiomyopathy (Loeffler cardiomy-
opathy) or acute fulminant myocarditis (also called acute necrotizing eosinophilic 
myocarditis) [60]. The definite diagnosis of eosinophilic myocarditis can only be 
achieved with an endomyocardial biopsy, although clinicians often base the diagno-
sis on laboratory findings and imaging examinations, mainly cardiac MR [1, 9].
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In most cases, eosinophilia can be detected in peripheral blood samples and 
this finding together with cardiac symptoms should always raise suspicions of 
eosinophilic myocarditis. However, in the early stage of the disease, peripheral 
eosinophilia may be absent and it may not develop at all in a subgroup of patients. 
Circulating markers of inflammation and myocardial injury are often increased 
and natriuretic peptides increase in parallel with the severity of the heart failure 
syndrome. Normal laboratory tests do not, however, exclude the presence of the 
disease [60].
The ECG is often abnormal, mainly demonstrating ST-T segment abnormalities, 
but this is neither sensitive nor specific for eosinophilic myocarditis. The echo-
cardiogram is of pivotal importance with respect to excluding other heart failure 
etiologies, evaluating left ventricular systolic and diastolic function and monitoring 
the presence of pericardial effusion. Cardiac MR allows for the identification of 
edema and diffuse foci of delayed enhancement reflecting myocardial inflamma-
tion, necrosis and fibrosis. In stable patients, it is reasonable to perform cardiac 
MR imaging prior to endomyocardial biopsy, as the former may help to identify 
focal pathology through late enhancement and guide myocardial tissue sampling. 
However, in unstable patients an endomyocardial biopsy should be prioritized [60, 
62, 63]. Eosinophilic myocarditis, particularly in its fulminant form, is associated 
with high in-hospital mortality, but owing to the rarity of the disease, no reliable 
data on mortality rates are available. Its incidence and prevalence are probably 
under-estimated, as the disease is most usually discovered post-mortem [60].
The treatment and prognosis of eosinophilic myocarditis depends on its etiology. 
In the acute phase, restriction of physical activity is an important measure. In selected 
patients, particularly in those with suspected autoreactive etiology and negative 
virology, early treatment with corticosteroids has resulted in advantageous outcomes 
[64]. Nevertheless, the evidence supporting corticosteroid therapy is limited, deriv-
ing from small, non-randomized studies. Moreover, the initial dosage and treatment 
duration vary between different reports and, therefore, no evidence-based recom-
mendations can be presented. It is not unreasonable, however, to adjust the steroid 
dose and treatment duration to the severity of the disease and the primary underlying 
disorder [60, 62, 64]. The monoclonal antibody benralizumab, which binds to the 
interleukin-5 receptor on the cell surface and causes apoptosis of eosinophils, has 
recently been advocated as a promising new therapeutic strategy for eosinophil 
myocarditis [60].
11. Conclusions
Inflammatory cardiomyopathy refers to a diverse group of disorders in which 
inflammation of the heart muscle is accompanied by disturbances of cardiac struc-
ture and/or function. The diagnosis of these disorders remains challenging despite 
recent advances in imaging and molecular biology techniques. Together with careful 
anamnestic enquiry, physical examination and laboratory tests, a comprehensive 
diagnostic work-up, including both non-invasive and invasive methods, is required 
to reach a conclusion with respect to identification, management and prognosis. 
Although cardiac MR and PET/CT represent fundamental non-invasive diagnostic 
methods, endomyocardial biopsy remains the gold standard. Regular treatment 
of inflammatory cardiomyopathies is based on the guideline-directed therapy for 
heart failure and arrhythmias. More targeted therapies, including immunomodu-
lating treatment, can be indicated only when histopathological findings from 
the endomyocardial biopsy are known. However, owing to a lack of evidence, an 
individual assessment of each patient is of vital importance for the management of 
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inflammatory cardiomyopathies. Large prospective multicenter randomized studies 
are needed to generate evidence-based treatment recommendations in this specific 
group of patients.
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